The awards support research focused on preventing ovarian cancer recurrence after surgery and developing more accessible tools to guide personalized cancer treatment.

Brazilian researchers have discovered why the guardian of the genome, p53, is uniquely prone to structural failure compared to its more robust relatives. The study identifies molecular gaps and structural frustration that trigger p53 cancer-linked aggregation, revealing how the protein sequence balances flexibility with vulnerability. These findings, stemming from over twenty years of research, provide a new roadmap for next-generation cancer therapies focused on stabilizing this critical protein.

The 2026 Gruber Genetics Prize is being awarded to Alan G Hinnebusch, PhD, a Distinguished Investigator at the National Institutes of Health, for his pioneering work that established both the paradigm and the detailed mechanism of translational control that underlies the Integrated Stress Response, a pivotal mechanism whereby eukaryotic cells reprogram protein synthesis under stress.

In a series of forward genetics screens in budding yeast, Hinnebusch identified mutations in the kinase Gcn2, which phosphorylates the key translation initiation factor eIF2, and Gcn4, a key transcription factor that controls genes involved in amino acid biosynthesis.

Hinnebusch demonstrated that the phosphorylation of eIF2 suppresses global protein synthesis and selectively induces the master transcription factor Gcn4. This translational control mechanism is broadly conserved from yeast to humans.

Hinnebusch’s work has led to a greater understanding of how cells respond to stressors such as amino acid starvation and viral infections. Dysregulation of the integrated stress response has been linked to neurodegeneration, metabolic disorders and cancer.

Having surgery for rectal cancer at a hospital accredited by the National Accreditation Program for Rectal Cancer was associated with a significant reduction in cancer remaining at the edges of the tumor site, compared to having the same surgery at a non-accredited hospital.

In the first U.S. randomized placebo-controlled trial of its kind, researchers from Penn State College of Medicine found that smokers who switched from traditional cigarettes to pod-based salt-nicotine e-cigarettes were three times more likely to quit smoking within six weeks and were exposed to lower levels of harmful tobacco-related toxicants.

Researchers at the Francis Crick Institute have revealed that sensory nerve signals interfere with the immune system’s response to lung cancer. This previously unrecognised neuroimmune connection could be targeted to improve responses to immunotherapy.

 

Researchers at McGill University have discovered a centuries-old genetic mutation that helps to explain why some French‑Canadians in Quebec are at an elevated risk of pancreatic cancer. Until quite recently, standard genetic tests have not been able to identify this “jumping gene” cause.

The findings, published in the Journal of Medical Genetics, suggest better-targeted genetic testing could help identify people at higher cancer risk who were previously missed.

A team of researchers from USC have conducted a head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. It is the first study to analyze two new drugs, lorlatinib and brigatinib, outside of clinical trials. The findings, just published in the journal Lung Cancer, could help patients and physicians make more informed decisions about treatment.